Sirtris Pharmaceuticals is a biopharmaceutical company discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Its drug candidates are designed to mimic the beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of an enzyme called SIRT1, a member of a recently discovered class of enzymes called sirtuins. 

Sirtris has been acquired by GlaxoSmithKline. 

(NYSE:GSK)